MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2025-09-30.

Cash Flow Overview

Free Cash flow
-$46,649K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-56,755 -120,723
Stock-based compensation
5,980 16,489
Loss on sale of property and equipment
--62
Non-cash operating lease expense
58 1,777
Depreciation and amortization
23 176
Net accretion of investments in marketable securities
612 2,185
Impairment of held for sale assets
0 378
Non-cash interest expense and amortization of debt issuance costs
213 303
Other noncash expenses
39 -
Prepaid expenses and other current assets
326 -1,111
Accounts payable
-96 -2,663
Accrued liabilities
4,865 -4,650
Operating lease liabilities
39 -1,873
Other assets
-1 54
Net cash used in operating activities
-46,633 -111,852
Purchases of marketable securities
0 82,868
Cash paid for acquisition of assets
0 0
Proceeds from maturities of marketable securities
51,246 157,341
Proceeds from sale of property and equipment
87 84
Purchases of property and equipment
16 -
Net cash provided by investing activities
51,317 74,557
Net proceeds from term loan
-136 18,398
Proceeds from exercise of stock options
0 0
Proceeds from employee stock purchase plan purchases
0 59
Payments for offering costs in connection with at-the-market offering and initial public offering
0 -
Net cash provided by financing activities
-136 18,457
Net change in cash and cash equivalents and restricted cash
4,548 -18,838
Cash and cash equivalents at beginning of period
143,361 -
Cash and cash equivalents at end of period
129,071 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Neumora Therapeutics, Inc. (NMRA)

Neumora Therapeutics, Inc. (NMRA)